-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Revolution Medicines, Raises Price Target to $122

Benzinga·02/02/2026 18:01:37
Listen to the news
JP Morgan analyst Brian Cheng maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $92 to $122.